Pancreatic Cancer Research

ResearcherUniversity of North Carolina at Chapel HillActive in the last 2 years

Samuel Lai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4721-528X; OpenAlex author ID A5079956311; NIH RePORTER profile ID 10055327. Sources: OpenAlex.

Their work

Papers
1 (first author 0, last author 1)
Trials
0
Grants
2
Labs led
1
Collaborators
2
Papers, trials and grants by year

2021: 1 grant · 2022: none · 2023: none · 2024: 1 grant · 2025: 1 paper

Papers 1

  1. Bispecific Siglec-15/T cell antibody (STAB) activates T cells and suppresses pancreatic ductal adenocarcinoma and non-small cell lung tumors in vivo. Last author DOI 10.7150/thno.103372↗

Grants 2

  1. Engineering Siglec15/TGF-beta targeted bispecific antibodies that modulate the tumor microenvironment and enhances T-cell immunotherapy against pancreatic canc… R21CA273983↗
  2. Overcoming anti-PEG immunity to restore prolonged circulation and efficacy of PEGylated therapeutics R01HL141934↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. William C Zamboni · 1 shared grant, 2021 · strength 0.56
  2. Limei Shen · 1 shared paper, 2025 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.